Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.
Teva Pharmaceuticals (NYSE:TEVA) on June 24, 2024, announced the authorized launch of a generic version of Novo Nordisk's Victoza® as injected liraglutide and noted that Victoza had annual sales of $1 ...
Rybelsus (semaglutide) is a prescription drug used to manage blood sugar levels in adults with type 2 diabetes. Rybelsus can cause mild to severe side effects that may include constipation and ...
Results that may be inaccessible to you are currently showing.